Table 2 Total characteristics of therapy and prognosis
From: Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study
Clinicopathological Factor | Number |
|---|---|
Operation | 211 (100%) |
Complete Surgical Staging | 114 (54.0%) |
Maximal Resection | 97 (46.0%) |
Residual Disease | |
 R0 | 142 (67.3%) |
 R1(< 1 cm) | 13 (6.2%) |
 1–2 cm | 7 (3.32%) |
  > 2 cm | 8 (3.79%) |
 Record not found | 41 (19.4%) |
 Second Operation | 11 (5.25%) |
Abdominal Dropsy | |
 0 | 78 (37.0%) |
  < 500 ml | 81 (38.4%) |
  > 500 ml | 34 (16.1%) |
 Record not found | 18 (8.5%) |
 Lymph Nodes Excision (LMN) | 188 (89.1%) |
 No | 23 (10.9%) |
 Pelvic Region Only | 2 (0.9%) |
 Pelvic & Abdominal region | 186 (88.2%) |
Surgery to Conserve Fertility | 8 (3.8%) |
 Chemotherapy Regimens | 177 (83.9%) |
  Platinum-based chemotherapy (PBC) | 174 (82.3%) |
  Platinum-free chemotherapy | 3 (1.4%) |
  TC | 150 (71.1%) |
  Others | 27 (13.0%) |
FIGO stage | |
 I | 114 (54.0%) |
 II | 39 (18.5%) |
 III | 54 (25.6%) |
 IV | 4 (1.9%) |
Chemotherapy Treatment Course | |
  < 6 | 39 (18.5%) |
  ≥ 6 | 138 (65.4%) |
 Death | 29 (13.7%) |
 Relapse | 48 (22.7%) |